Published in Br J Cancer on August 26, 2014
Inflammatory Response After Laparoscopic Versus Open Resection of Colorectal Liver Metastases: Data From the Oslo-CoMet Trial. Medicine (Baltimore) (2015) 1.41
New findings on primary and acquired resistance to anti-EGFR therapy in metastatic colorectal cancer: do all roads lead to RAS? Oncotarget (2015) 1.02
Long non-coding RNA HULC as a novel serum biomarker for diagnosis and prognosis prediction of gastric cancer. Oncotarget (2016) 0.95
The Prognostic Value of Circulating Cell-Free DNA in Colorectal Cancer: A Meta-Analysis. J Cancer (2016) 0.82
Diagnostic and prognostic value of SHOX2 and SEPT9 DNA methylation and cytology in benign, paramalignant, and malignant ascites. Clin Epigenetics (2016) 0.77
Quantitative analysis of cell-free DNA in ovarian cancer. Oncol Lett (2015) 0.76
Cell-free DNA as a diagnostic marker for cancer: current insights. Onco Targets Ther (2016) 0.75
Plasma Circulating Cell-free DNA Integrity as a Promising Biomarker for Diagnosis and Surveillance in Patients with Hepatocellular Carcinoma. J Cancer (2016) 0.75
Circulating Cell-Free DNA in Dogs with Mammary Tumors: Short and Long Fragments and Integrity Index. PLoS One (2017) 0.75
Clinical relevance of cell-free DNA in gastrointestinal tract malignancy. Oncotarget (2016) 0.75
Abnormal DNA methylation as a cell-free circulating DNA biomarker for colorectal cancer detection: A review of literature. World J Gastrointest Oncol (2017) 0.75
Prediction of cancer progression in a group of 73 gastric cancer patients by circulating cell-free DNA. BMC Cancer (2016) 0.75
Alteration of the exDNA profile in blood serum of LLC-bearing mice under the decrease of tumour invasion potential by bovine pancreatic DNase I treatment. PLoS One (2017) 0.75
Assessment of the circulating cell-free DNA marker association with diagnosis and prognostic prediction in patients with lymphoma: a single-center experience. Ann Hematol (2017) 0.75
Detection of PIK3CA Mutations in Plasma DNA of Colorectal Cancer Patients by an Ultra-Sensitive PNA-Mediated PCR. Mol Diagn Ther (2017) 0.75
Global cancer statistics. CA Cancer J Clin (2011) 185.92
Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer (2010) 90.16
Biomarkers in cancer staging, prognosis and treatment selection. Nat Rev Cancer (2005) 6.46
DNA fragments in the blood plasma of cancer patients: quantitations and evidence for their origin from apoptotic and necrotic cells. Cancer Res (2001) 5.45
Estimation of the Youden Index and its associated cutoff point. Biom J (2005) 5.40
Free DNA in the serum of cancer patients and the effect of therapy. Cancer Res (1977) 4.59
Quantification of free circulating DNA as a diagnostic marker in lung cancer. J Clin Oncol (2003) 4.22
Analysis of early human immunodeficiency virus type 1 DNA synthesis by use of a new sensitive assay for quantifying integrated provirus. J Virol (2003) 3.18
Cell-free DNA in human blood plasma: length measurements in patients with pancreatic cancer and healthy controls. Pancreas (1998) 2.03
Analysis of mutations in DNA isolated from plasma and stool of colorectal cancer patients. Gastroenterology (2008) 1.74
Prediction of breast tumor progression by integrity of free circulating DNA in serum. J Clin Oncol (2006) 1.73
Increased plasma DNA integrity in cancer patients. Cancer Res (2003) 1.59
Increased integrity of free circulating DNA in sera of patients with colorectal or periampullary cancer: direct quantitative PCR for ALU repeats. Clin Chem (2006) 1.58
Circulating tumour markers can define patients with normal colons, benign polyps, and cancers. Br J Cancer (2011) 1.30
Circulating plasma DNA as diagnostic biomarker in non-small cell lung cancer. Lung Cancer (2008) 1.25
AluGene: a database of Alu elements incorporated within protein-coding genes. Nucleic Acids Res (2004) 1.19
A sensitive method to quantify human long DNA in stool: relevance to colorectal cancer screening. Cancer Epidemiol Biomarkers Prev (2006) 1.14
Circulating nucleic acids in plasma and serum: past, present and future. Curr Opin Mol Ther (2004) 1.13
Free DNA and carcinoembryonic antigen serum levels: an important combination for diagnosis of colorectal cancer. Clin Cancer Res (2006) 1.08
Elevated level of cell-free plasma DNA is associated with breast cancer. Arch Gynecol Obstet (2007) 1.05
Cell-free circulating DNA in Hodgkin's and non-Hodgkin's lymphomas. Ann Oncol (2009) 1.03
Circulating nucleic acids and proteomics of plasma/serum: clinical utility. Ann N Y Acad Sci (2004) 1.03
Levels of circulating cell-free nuclear and mitochondrial DNA in benign and malignant ovarian tumors. Obstet Gynecol (2008) 0.99
Quantitative analysis of plasma DNA in colorectal cancer patients: a novel prognostic tool. Ann N Y Acad Sci (2006) 0.98
Persistent aberrations in circulating DNA integrity after radiotherapy are associated with poor prognosis in nasopharyngeal carcinoma patients. Clin Cancer Res (2008) 0.97
Circulating cell-free DNA in plasma of melanoma patients: qualitative and quantitative considerations. Clin Chim Acta (2011) 0.96
Measurement of circulating cell-free DNA levels by a new simple fluorescent test in patients with primary colorectal cancer. Am J Clin Pathol (2011) 0.95
Increased integrity of circulating cell-free DNA in plasma of patients with acute leukemia. Clin Chem Lab Med (2010) 0.93
Joint confidence region estimation for area under ROC curve and Youden index. Stat Med (2013) 0.93
DNA integrity in plasma and serum of patients with malignant and benign diseases. Ann N Y Acad Sci (2008) 0.92
Molecular profiling and risk stratification of adenocarcinoma of the colon. J Surg Oncol (2007) 0.92
Cell-free circulating DNA: diagnostic value in patients with testicular germ cell cancer. J Urol (2008) 0.91
Allelic imbalance on 12q22-23 in serum circulating DNA of melanoma patients predicts disease outcome. Cancer Res (2004) 0.90
Cell-free circulating DNA: Diagnostic value in patients with renal cell cancer. Anticancer Res (2010) 0.89
Comparison of four DNA extraction methods for detecting Mycobacterium tuberculosis by real-time PCR and its clinical application in pulmonary tuberculosis. J Thorac Dis (2013) 0.89
DNA integrity assay: a plasma-based screening tool for the detection of prostate cancer. Clin Cancer Res (2006) 0.86
Increased plasma DNA integrity index in head and neck cancer patients. Int J Cancer (2006) 0.86
Accuracy and cut-off point selection in three-class classification problems using a generalization of the Youden index. Stat Med (2010) 0.86
Prediction of clear cell renal cell carcinoma by integrity of cell-free DNA in serum. Urology (2009) 0.85
Total serum DNA and DNA integrity: diagnostic value in patients with hepatitis B virus-related hepatocellular carcinoma. Pathology (2012) 0.85
Circulating cell-free DNA in serum as a biomarker of colorectal cancer. J Clin Pathol (2013) 0.85
Value of circulating cell-free DNA in diagnosis of hepatocelluar carcinoma. World J Gastroenterol (2013) 0.84
Plasma DNA as a molecular marker for completeness of resection and recurrent disease in patients with esophageal cancer. Arch Surg (2007) 0.83
Alu-based cell-free DNA: a potential complementary biomarker for diagnosis of colorectal cancer. Clin Biochem (2012) 0.82
Plasma cell-free DNA and its DNA integrity as biomarker to distinguish prostate cancer from benign prostatic hyperplasia in patients with increased serum prostate-specific antigen. Int Urol Nephrol (2013) 0.81
Alu PCR. Methods Mol Biol (2011) 0.79
Pleural fluid cell-free DNA integrity index to identify cytologically negative malignant pleural effusions including mesotheliomas. BMC Cancer (2012) 0.79
Utilization of nuclear matrix proteins for cancer diagnosis. Crit Rev Eukaryot Gene Expr (1996) 0.79